方法：将21例符合入组条件的，就诊于我院的PCV患者随机分为两组，A组：3+Q12W方案(固定给药组)，9例9眼，连续3次每4wk玻璃体腔注射0.5mg康柏西普眼用注射液，之后每12wk给药1次； B组：3+TAE方案(延长给药组)，12例12眼，连续3次每4wk玻璃体腔注射0.5mg康柏西普眼用注射液，之后根据每次访视评估结果确定下次给药的时间，至下一次访视/治疗间隔最短4wk，最长不超过12wk。分别于治疗12、48wk时比较两组最佳矫正视力(BCVA)及中心视网膜厚度(CRT)及给药的次数。

结果：治疗12、48wk时固定给药组的BCVA分别为74.78±11.23、74.67±13.94个字母，分别比治疗前提高了7.00±4.21、6.89±4.48个字母； 在治疗12、48wk时延长给药组BCVA分别为77.83±5.46、77.58±8.59个字母，分别比治疗前提高了8.75±7.54、8.50±5.60个字母。注射后12、48wk固定给药组黄斑CRT分别为276.33±44.34、240.56±40.11μm，分别比治疗前下降了43.22±42.21、79.00±53.64μm； 注射后第12、48wk延长给药组黄斑CRT分别为271.58±63.08、241.00±43.91μm，分别比治疗前下降了57.42±45.33、88.00±61.16μm。固定给药组和延长给药组球内注射康柏西普次数分别为6.00±0.00、7.75±1.14次。

结论：两种康柏西普给药方案均可以减轻PCV患者CRT，提高视力，固定给药组球内注射的次数少于延长给药组。

METHODS: Twenty-one patients with polypoidal choroidal vasculopathy who met the inclusion criteria and were treated in our hospital were randomly divided into two groups. The group A(9 patients and 9 eyes)was treated with 3+Q12W scheme, namely, 0.5mg conbercept ophthalmic injection was intravitreally injected every 4wk for 3 consecutive times, and then 1 time every 12wk. In the group B(12 patients and 12 eyes), 3+TAE scheme was carried out, that is 0.5mg conbercept ophthalmic injection was intravitreally injected every 4wks for 3 consecutive times. The time of next injection was determined according to the evaluation results of each visit. The interval to the next visit/treatment was ≥ 4wk and ≤ 12wk. The best corrected visual acuity(BCVA), central retinal thickness(CRT)and the frequency of injection were compared between the two groups at 12 and 48wk after treatment, respectively.

RESULTS: BCVA of the group A was 74.78±11.23 letters and 74.67±13.94 letters at 12 and 48wk after treatment, which increased by 7.00±4.21 letters and 6.89±4.48 letters at the baseline before treatment, respectively. BCVA in the group B was 77.83±5.46 letters and 77.58±8.59 letters respectively at 12 and 48wk after treatment, which were 8.75±7.54 letters and 8.50±5.60 letters higher than the baseline before treatment. At the 12 and 48wk after injection, the average CRT in the group A was 276.33±44.34μm and 240.56±40.11μm, respectively, which were 43.22±42.21μm and 79.00±53.64μm lower than the baseline before treatment. At the 12 and 48wk after injection, the average CRT in the group B was 271.58±63.08μm and 241.00±43.91 μm, which were 57.42±45.33μm and 88.00±61.16μm lower than the baseline before treatment, respectively. The average times of intravitreal injection of conbercept were 6.00±0.00 and 7.75±1.14 times in the 3+Q12W group and the 3+TAE group, respectively.

CONCLUSION: Two different regimens of conbercept could reduce the CRT and improve the visual acuity of the patients with polypoidal choroidal vasculopathy. And the times of intravitreal injection in the 3+Q12W administration group were less than those in the3+TAE administration group.